[
 {
  "title": "Annual Physical Health Examination",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Millions of Americans schedule an annual physical health examination. During their visit, many can expect to get their blood drawn for a standard lipid panel, which ultimately provides the patient with a readout of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TGs).",
  "content_length": 354,
  "content_tokens": 77,
  "embedding": []
 },
 {
  "title": "Apolipoprotein B (apoB) Test",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "What virtually nobody among them will get is an apolipoprotein B (apoB) test. Yet this is considered the ideal, if not essential, measurement to assess lipoprotein-related atherosclerotic cardiovascular disease (ASCVD) risk, according to recent guidelines.",
  "content_length": 256,
  "content_tokens": 56,
  "embedding": []
 },
 {
  "title": "Basics of Lipids and Lipoproteins",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Lipids are a class of molecules that are not soluble in water and therefore cannot circulate in plasma (the liquid flowing through our arteries and veins), as plasma is 90% water, any more than you can dissolve a tablespoon of olive oil in a glass of water. A lipoprotein is essentially a vehicle that carries these lipids through plasma.",
  "content_length": 338,
  "content_tokens": 70,
  "embedding": []
 },
 {
  "title": "Density of Lipoproteins",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The density of lipoproteins were discovered many decades ago by drawing blood into a sealed collection tube, spinning the living daylights out of that tube, a process called ultracentrifugation, and seeing where they settled. Most lipoproteins then became classified by their density.",
  "content_length": 284,
  "content_tokens": 59,
  "embedding": []
 },
 {
  "title": "Apolipoprotein B (apoB)",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Lipoproteins are not only classified by their density, but laboratory techniques allow for the measurement of their apolipoproteins. While there are at least 10 classes, and several subclasses, of apolipoproteins, our focus here is on apolipoprotein B (apoB).",
  "content_length": 259,
  "content_tokens": 61,
  "embedding": []
 },
 {
  "title": "Apolipoprotein B-containing Lipoproteins",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "It turns out that each CM, VLDL, IDL, LDL, and Lp(a) has one, and only one, apoB per particle. This allows apoB measurement to serve as a particle concentration for these lipoproteins.",
  "content_length": 184,
  "content_tokens": 54,
  "embedding": []
 },
 {
  "title": "Standard Lipid Panel",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "When you get a standard lipid panel and the familiar readout of TC, LDL-C, HDL-C, and TG, it’s showing you the mass of these lipids (i.e., cholesterol, except in the case of the TG measurement) per unit volume of plasma.",
  "content_length": 220,
  "content_tokens": 60,
  "embedding": []
 },
 {
  "title": "LDL-C Calculation",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Although LDL-C can be directly measured, LDL-C reported by most labs is usually calculated based on direct measurements of TC, HDL-C, and TG, and is called the Friedewald formula.",
  "content_length": 179,
  "content_tokens": 42,
  "embedding": []
 },
 {
  "title": "Non-HDL-C Measurement",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The non-HDL-C measurement, shown in Table 2, is a metric that is increasing in popularity for predicting ASCVD risk. By subtracting HDL-C from TC, the resulting non-HDL-C is the sum of all cholesterol carried within the apoB-containing lipoproteins.",
  "content_length": 249,
  "content_tokens": 64,
  "embedding": []
 },
 {
  "title": "Apolipoprotein B (apoB) Level",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "In a recent review article in JAMA Cardiology, Allan Sniderman and his colleagues make the case that apolipoprotein B (apoB) level—rather than LDL-C, non-HDL-C, or even LDL particle count (LDL-P)—is the best measure of potentially atherogenic lipoproteins.",
  "content_length": 256,
  "content_tokens": 71,
  "embedding": []
 },
 {
  "title": "Concordance and Discordance",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Important in understanding why lipidologists like Dr. Sniderman are increasingly arguing for more direct measurements of the number of lipoproteins themselves, rather than the cholesterol or triglycerides contained within them, is the concept of concordance and discordance.",
  "content_length": 274,
  "content_tokens": 51,
  "embedding": []
 },
 {
  "title": "Atherosclerotic Cardiovascular Disease Risk",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "This point is critical in determining patient risk for atherosclerotic cardiovascular disease (ASCVD). More technically, it’s apoB-containing particle levels. When I refer to apoB levels or apoBs, I’m talking about the concentration or number of lipoproteins that have an apoB attached to it. The composition and sizes of apoB-containing particles are not set in stone. They vary from person to person and particle to particle, depending on the person’s metabolic health and genetic makeup.",
  "content_length": 490,
  "content_tokens": 113,
  "embedding": []
 },
 {
  "title": "Particle Concentrations and Cardiovascular Risk",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Why are particle concentrations better at predicting risk than cholesterol concentrations? A greater number of apoB-containing particles leads to a greater number of these particles that enter and get trapped within the wall of the artery, leading to a greater amount of injury to the arterial wall. It’s somewhat stochastic: the more shots on goal (particles hitting the artery wall), the more chances of goals (particles getting through the cracks).",
  "content_length": 451,
  "content_tokens": 90,
  "embedding": []
 },
 {
  "title": "Reducing Cardiovascular Risk",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "This mechanism of atherogenesis offers at least a partial solution: lower the number of apoB-containing lipoproteins. A smaller number of apoB-containing particles leads to a smaller number of these particles that enter and get trapped within the wall of the artery, and therefore less injury to the arterial wall. Beyond lifestyle—smoking cessation, blood pressure control, correcting insulin resistance, and more—we know that lipid-lowering drugs like statins, ezetimibe, PCSK9 inhibitors, and bile sequestrants all lower apoB.",
  "content_length": 529,
  "content_tokens": 118,
  "embedding": []
 },
 {
  "title": "Importance of apoB Measurement",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The only way for a clinician to know when apoB and cholesterol measurements are concordant or discordant is to measure apoB and compare it to the lipid profile. In virtually all trials when discordance is present, ASCVD-risk better follows the apoB. If they are correct, and apoB is our best measure of risk, this makes for a very compelling case for including apoB measurement—and perhaps even replacing LDL-C and non-HDL-C altogether—in clinical care.",
  "content_length": 453,
  "content_tokens": 108,
  "embedding": []
 },
 {
  "title": "Knowing Your apoB Level",
  "date": "December 22, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "While there is more to ASCVD risk than just lipoproteins, if you don’t know your apoB level, you are not fully taking advantage of the tools at our disposal to estimate your risk of cardiovascular and cerebrovascular disease. Know your risks and manage them accordingly.",
  "content_length": 270,
  "content_tokens": 61,
  "embedding": []
 }
]